An FDA advisory panel on Thursday unanimously recommended approval of Moderna’s mRNA flu vaccine, mFlusiva, for adults 50 to 64 and 65 and older after a late-stage trial found it was about 27% more effective than a standard flu shot. If the FDA and CDC clear it, clinicians could soon have the first mRNA influenza vaccine — a potentially faster-to-update option for older patients at highest risk of hospitalization.

The Move

• The FDA’s Vaccines and Related Biological Products Advisory Committee backed Moderna’s shot for two older-adult age groups.

• For adults 65 and up, advisers attached a condition: Moderna must run an additional post-market clinical trial.

• The recommendation follows an uneven review process in which the FDA initially declined to review the application before reversing course.

Why It Matters For Care

• Older adults account for most flu hospitalizations, and vaccine effectiveness with current products can swing widely year to year.

• Moderna says its mRNA platform can move from strain selection to rollout in two to three months, versus roughly six months for traditional flu shots.

• That shorter timeline could improve strain matching and, if borne out in practice, give clinicians a more effective option for patients 50+.

Between The Lines

• This is both a vaccine decision and a political test of mRNA technology under HHS Secretary Robert F. Kennedy Jr., who has sharply criticized mRNA COVID-19 vaccines.

• HHS recently canceled nearly $500 million in mRNA vaccine research funding, adding uncertainty around how enthusiastically the administration will handle rollout.

• Advisers appeared persuaded by the platform’s speed and future flexibility, even as they pressed Moderna on whether its comparator trial reflected the higher-dose flu shots often used in seniors.

What To Watch

• The FDA still must make the final approval decision, and the agency currently lacks a permanent commissioner and vaccine chief.

• The CDC’s advisory committee would typically weigh in next, but its ability to convene has been blocked by a federal judge.

• Key practical question: whether approval and CDC action come in time for patients to access the vaccine this fall.

Source: NBC News Health